Recent Science press releases & news

Presswire is the leading news platform where businesses, educational institutions, news reporters, etc. come together to share compelling news stories that transform opinions and impact lives. Presswire has an extensive media contact list for press releases, reaching millions of contacts. We ensure that your story lands on the right business desks and the right mass media outlets. To begin your press release distribution, send your stories to Presswire or by filling out the form here.

1

Psikosmos book leads to new physical theory of the Cosmos

André Moravec's work builds an imaginary world to explain the physical world.

1

Detecting Multiple Diseases At Once: EU-Funded Didida Project Develops A Cost-Effective Mobile Based Solution In Africa

 

[PRESSWIRE] Nairobi - November 9, 2022 -- The Digital Innovations and Diagnostics for Infectious Diseases in Africa (Didida) had its official kick-off at the Strathmore University. Didida is an ambitious project to develop reliable, low-cost, mobile phone-connected tests to help detect multiple infectious diseases and non-communicable diseases (NCD) at once in sub-Saharan Africa. Didida also plans to invest in digital health infrastructure and train a new generation of African experts to meet the health needs of the continent.

1

World’s Leading AI Drone Learning Platform Launched with Free Access

 

[PRESSWIRE] London, UK - 30.09.22 -- COPTRZ Ltd, have launched their new drone learning experience platform (LXP) platform COPTRZ ACADEMY. COPTRZ claim that this is the leading platform of its type anywhere in the World.

1

CEBINA publishes data demonstrating the anti-histamine azelastine inhibits infection by major variants of SARS-CoV-2

 

[PRESSWIRE] Austria - 04.07.22 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today announces the publication of research results demonstrating that the commonly used anti-histamine, azelastine, is a potent inhibitor of major variants of SARS- CoV-2 in the peer-reviewed journal Frontiers in Pharmacology (1).

1

NemaLife and UC Davis enter into a research partnership to test the therapeutic potential of several novel psychoplastogens developed in David E. Olson’s Lab

 

[PRESSWIRE] LUBBOCK, TX -- April 19, 2022 – NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.

1

Zero Carbon Capital closes first £10m of £30m fund for pre-seed & seed decarbonisation investments

 

[PRESSWIRE] London, UK - 14.04.22 -- Zero Carbon Capital Ltd has today announced the first close of the new Zero Carbon Capital 2022 LP fund. They have raised £10m toward a target of £30m to invest in extraordinary early-stage European companies building innovative, scientific solutions to the biggest, hardest challenges of decarbonisation.

1

Eveliqure announces the publication of positive Phase I clinical data for its vaccine candidate against Shigellosis and ETEC

 

[PRESSWIRE] Vienna - 23rd February 2022 -- Eveliqure Biotechnologies GmbH, a clinical stage biotechnology company, today announces the publication of positive Phase I data with ShigETEC, its vaccine candidate against Shigellae and enterotoxic E. coli in the peer-reviewed journal Vaccines (https://doi.org/10.3390/vaccines10020340).

Azelastine - the active drug in anti-allergy nasal sprays demonstrated to have potent anti-viral effect on the Omicron variant of SARS-CoV-2

 

[PRESSWIRE] Vienna - 03 February, 2022 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator with its partner URSAPHARM Arzneimittel GmbH, today announce new results demonstrating that azelastine, the active drug in Pollival®, URSAPHARM’s widely available anti-allergy nasal spray, is an effective anti-viral against the globally dominant omicron SARS-CoV-2 variant in laboratory conditions.

1

Using Smart Sensors and Cloud-based Analytics, Canary’s 20-minute Handheld COVID-19 Saliva-based Molecular Test with PCR Quality Results Achieves CE Mark

• Rapid molecular PCR-like accurate saliva-based test delivers 95% sensitivity and 98% specificity in symptomatic and asymptomatic individuals with SARS-CoV-2 including variants
• Designed for point-of-care (POC) diagnosis, ease of use, rapid and cost-effective mass-screening
• A mobile-enabled, multiplex platform and connected solution enables efficient real-time reporting of results, track & trace, and surveillance

1

CEBINA reports broad anti-viral potency of azelastine, an antihistamine widely available as a nasal spray, has potential for use against influenza and RSV infections in addition to SARS-CoV-2 and its variants of concern including the Omicron variant

 

[PRESSWIRE] Austria - 10.12.21 -- CEBINA GmbH, Central European Biotech Incubator and Accelerator, today informs about the potential of the antihistamine drug azelastine hydrochloride to be an effective anti-viral approach against major respiratory viruses, such as SARS-CoV-2 and its variants, influenza and Respiratory Syncytial Virus (RSV).